Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03479723 · ClinicalTrials.gov registry record
Identification of Predictors for Coronary Plaque Erosion in Patients With Acute Coronary Syndrome
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 1,793
- Enrollment target
NCT03479723: Completed study, sponsored by Massachusetts General Hospital.
NCT03479723 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 1,793 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03479723 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 1,793 participants
- Enrollment target
Study Summary
The purpose of this study is to perform pooled analysis with data collected from 5 previously published studies and 8 unpublished datasets collected from international sites. The main goal of this study is to identify the predictors of plaque erosion.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,793 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2024-08-01 |
What the finished NCT03479723 record still lists
NCT03479723 is an observational study that tracks outcomes without assigning an intervention. Its 1,793 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT03479723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03479723 about?
NCT03479723 is a clinical study titled "Identification of Predictors for Coronary Plaque Erosion in Patients With Acute Coronary Syndrome". The purpose of this study is to perform pooled analysis with data collected from 5 previously published studies and 8 unpublished datasets collected from international sites. The main goal of this study is to identify the predictors of plaque erosion.
What is the current status of trial NCT03479723?
This trial is currently completed. The enrollment target is 1,793 participants. The study started on 2017-12-01. Estimated completion is 2024-08-01.
Who is sponsoring clinical trial NCT03479723?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
- NCT04980794 · 1,800 participants · NA
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
- NCT05258656 · 1,800 participants · NA
Childhood Activities Nutrition and Development Oversight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI